FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200396260> ?p ?o ?g. }

• W3200396260 endingPage "6970" @default.
• W3200396260 startingPage "6959" @default.
• W3200396260 abstract "Since 2009, multiple randomized trials have shown faster and deeper responses in CML patients treated with new-generation TKI (NG-TKI) compared to those treated with imatinib (IM). Are the same results observed in the general population?Patients were identified from the three French hematological malignancies population-based registries. All CML patients (ICD-O-3: 9875/3) diagnosed between 2006 and 2016 and resided in registries areas were included. The TKI generation effect on achievement of MMR in first-line therapy was assessed through a multivariate competitive risk analysis. An alluvial plot described the pathways leading to death.In total, 507 CML patients received TKI in first-line treatment, 22% were enrolled in a clinical trial. After adjustment, NG-TKI patients were significantly more likely to achieve MMR during first-line therapy than IM patients (HR: 1.88 CI95% [1.35-2.61]). At the end of follow-up, 212 patients were still in first-line therapy (46 of them died), 203 switched to second-line (43 subsequently died), 26 were on TFR from first-line (4 subsequently died), and 20 stopped their treatment (16 subsequently died).In this comprehensive real-life setting, the results were consistent with clinical trials. The results are not sufficient to conclude that a NG-TKI treatment is superior with regard to these patients, despite indications regarding differences between the TKI generation effect on survival and tolerance." @default.
• W3200396260 created "2021-09-27" @default.
• W3200396260 creator A5013092254 @default.
• W3200396260 creator A5031034999 @default.
• W3200396260 creator A5044166434 @default.
• W3200396260 creator A5048097062 @default.
• W3200396260 creator A5060476623 @default.
• W3200396260 creator A5070207000 @default.
• W3200396260 creator A5080283231 @default.
• W3200396260 creator A5081871516 @default.
• W3200396260 date "2021-09-22" @default.
• W3200396260 modified "2023-10-12" @default.
• W3200396260 title "Second‐ or third‐generation tyrosine kinase inhibitors in first‐line treatment of chronic myeloid leukemia in general population: Is there a real benefit?" @default.
• W3200396260 cites W1887153209 @default.
• W3200396260 cites W1968747503 @default.
• W3200396260 cites W2016953305 @default.
• W3200396260 cites W2020152925 @default.
• W3200396260 cites W2034469570 @default.
• W3200396260 cites W2036193982 @default.
• W3200396260 cites W2042528156 @default.
• W3200396260 cites W2052923507 @default.
• W3200396260 cites W2062594082 @default.
• W3200396260 cites W2067524254 @default.
• W3200396260 cites W2106266094 @default.
• W3200396260 cites W2113559481 @default.
• W3200396260 cites W2120729896 @default.
• W3200396260 cites W2155369095 @default.
• W3200396260 cites W2157826609 @default.
• W3200396260 cites W2193251487 @default.
• W3200396260 cites W2260921597 @default.
• W3200396260 cites W2339943063 @default.
• W3200396260 cites W2397234997 @default.
• W3200396260 cites W2513126620 @default.
• W3200396260 cites W2540096662 @default.
• W3200396260 cites W2746041041 @default.
• W3200396260 cites W2751098301 @default.
• W3200396260 cites W2766187515 @default.
• W3200396260 cites W2895117959 @default.
• W3200396260 cites W2919338231 @default.
• W3200396260 cites W2943039939 @default.
• W3200396260 cites W2972910330 @default.
• W3200396260 cites W3021092526 @default.
• W3200396260 cites W3200396260 @default.
• W3200396260 cites W4294553991 @default.
• W3200396260 doi "https://doi.org/10.1002/cam4.4186" @default.
• W3200396260 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8525157" @default.
• W3200396260 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34551198" @default.
• W3200396260 hasPublicationYear "2021" @default.
• W3200396260 type Work @default.
• W3200396260 sameAs 3200396260 @default.
• W3200396260 citedByCount "4" @default.
• W3200396260 countsByYear W32003962602021 @default.
• W3200396260 countsByYear W32003962602022 @default.
• W3200396260 countsByYear W32003962602023 @default.
• W3200396260 crossrefType "journal-article" @default.
• W3200396260 hasAuthorship W3200396260A5013092254 @default.
• W3200396260 hasAuthorship W3200396260A5031034999 @default.
• W3200396260 hasAuthorship W3200396260A5044166434 @default.
• W3200396260 hasAuthorship W3200396260A5048097062 @default.
• W3200396260 hasAuthorship W3200396260A5060476623 @default.
• W3200396260 hasAuthorship W3200396260A5070207000 @default.
• W3200396260 hasAuthorship W3200396260A5080283231 @default.
• W3200396260 hasAuthorship W3200396260A5081871516 @default.
• W3200396260 hasBestOaLocation W32003962601 @default.
• W3200396260 hasConcept C121608353 @default.
• W3200396260 hasConcept C126322002 @default.
• W3200396260 hasConcept C143998085 @default.
• W3200396260 hasConcept C2777583451 @default.
• W3200396260 hasConcept C2778729363 @default.
• W3200396260 hasConcept C2778820342 @default.
• W3200396260 hasConcept C2908647359 @default.
• W3200396260 hasConcept C2993493390 @default.
• W3200396260 hasConcept C3018840467 @default.
• W3200396260 hasConcept C3019894029 @default.
• W3200396260 hasConcept C535046627 @default.
• W3200396260 hasConcept C71924100 @default.
• W3200396260 hasConcept C99454951 @default.
• W3200396260 hasConceptScore W3200396260C121608353 @default.
• W3200396260 hasConceptScore W3200396260C126322002 @default.
• W3200396260 hasConceptScore W3200396260C143998085 @default.
• W3200396260 hasConceptScore W3200396260C2777583451 @default.
• W3200396260 hasConceptScore W3200396260C2778729363 @default.
• W3200396260 hasConceptScore W3200396260C2778820342 @default.
• W3200396260 hasConceptScore W3200396260C2908647359 @default.
• W3200396260 hasConceptScore W3200396260C2993493390 @default.
• W3200396260 hasConceptScore W3200396260C3018840467 @default.
• W3200396260 hasConceptScore W3200396260C3019894029 @default.
• W3200396260 hasConceptScore W3200396260C535046627 @default.
• W3200396260 hasConceptScore W3200396260C71924100 @default.
• W3200396260 hasConceptScore W3200396260C99454951 @default.
• W3200396260 hasFunder F4320322363 @default.
• W3200396260 hasIssue "20" @default.
• W3200396260 hasLocation W32003962601 @default.
• W3200396260 hasLocation W32003962602 @default.
• W3200396260 hasLocation W32003962603 @default.
• W3200396260 hasLocation W32003962604 @default.
• W3200396260 hasLocation W32003962605 @default.
• W3200396260 hasLocation W32003962606 @default.

• next